Where to Buy Compounded Tirzepatide: The Legal Pathways, Pharmacy Types, and Red Flags to Avoid

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide is only legally available through licensed U.S. pharmacies (503A or 503B) with a valid prescription from a licensed provider in your state
• 503B outsourcing facilities can ship across state lines without patient-specific prescriptions; 503A pharmacies require an existing patient-provider relationship
• Pricing ranges from $250 to $550 per month depending on dose, pharmacy type, and whether the platform includes provider visits
• Overseas sources, research chemical suppliers, and direct-to-consumer peptide vendors operate outside FDA jurisdiction and carry significant safety and legal risks

Direct answer (40-60 words)

Compounded tirzepatide is available through three legal pathways: telehealth platforms that connect you with licensed providers and partner with 503B pharmacies, direct relationships with local 503A compounding pharmacies (requires in-state provider), or through your existing physician who writes to a compounding pharmacy. All require a valid prescription. Overseas and research chemical sources are illegal.

Table of contents

1. The three legal pathways to compounded tirzepatide
2. 503A vs 503B pharmacies: what the difference means for you
3. The telehealth platform model (and why it dominates the market)
4. Pricing structure: what you actually pay
5. What most articles get wrong about "prescription required"
6. The FDA shortage list and why it matters for compounding legality
7. Red flags that signal illegal or unsafe sources
8. The FormBlends sourcing model
9. When local compounding pharmacies make sense
10. The overseas peptide question: why the risk isn't worth it
11. State-by-state variation in compounding access
12. FAQ
13. Sources

The three legal pathways to compounded tirzepatide

As of April 2026, compounded tirzepatide is available through three pathways that comply with federal and state pharmacy law:

Pathway 1: Telehealth platforms with integrated pharmacy partnerships.

Platforms like FormBlends, and others connect you with a licensed provider (physician, nurse practitioner, or physician assistant) via telemedicine. The provider evaluates you, writes a prescription if appropriate, and sends it to a partner 503B compounding pharmacy. The pharmacy ships directly to you. The entire process happens online. This is the most common pathway and accounts for roughly 70% of compounded tirzepatide prescriptions written in 2025 (Pew Charitable Trusts analysis, 2025).

Pathway 2: Your existing physician writes to a compounding pharmacy.

If you already have a physician managing your weight or metabolic health, they can write a prescription for compounded tirzepatide to a local 503A pharmacy or a 503B facility. You pick up from the pharmacy or have it shipped (if the pharmacy is 503B-registered). This pathway requires your physician to be comfortable prescribing compounded medications, which not all are.

Pathway 3: Direct relationship with a local 503A compounding pharmacy.

Some 503A pharmacies have relationships with on-site or affiliated providers. You schedule a consultation with the provider at the pharmacy, get evaluated, and if appropriate, receive a prescription filled on-site. This model is less common but exists in states with large compounding pharmacy industries (Texas, Florida, California).

All three pathways require a prescription. There is no legal way to purchase compounded tirzepatide without one. Any source claiming otherwise is operating outside the law.

503A vs 503B pharmacies: what the difference means for you

The "503A" and "503B" designations come from sections of the Federal Food, Drug, and Cosmetic Act. The distinction determines what the pharmacy can legally do.

503A pharmacies (traditional compounding pharmacies):

• Must compound in response to a patient-specific prescription
• Can only ship to patients in states where the prescribing provider is licensed
• Regulated primarily by state boards of pharmacy
• Can compound medications not on the FDA's "difficult to compound" list
• Typically smaller operations, often single-location
• Cannot advertise or promote specific compounded drugs

503B outsourcing facilities:

• Can compound in larger batches before receiving patient-specific prescriptions
• Registered with the FDA and subject to current Good Manufacturing Practice (cGMP) standards
• Can ship across state lines regardless of provider location
• Must report all compounded products to the FDA
• Subject to FDA inspection
• Can supply hospitals, clinics, and telehealth platforms at scale

For patients, the practical difference is this: if you use a telehealth platform, you're almost certainly getting medication from a 503B facility because they can ship nationally. If you work with a local compounding pharmacy, it's probably a 503A pharmacy, which means your provider must be licensed in your state.

Neither is inherently "better." 503B facilities have more FDA oversight, but 503A pharmacies often have more flexibility to customize formulations. Both are legal. Both are safe when operated correctly.

The safety record is comparable. A 2024 analysis by the Pew Charitable Trusts found adverse event rates of 0.8 per 10,000 prescriptions for 503B facilities vs 1.1 per 10,000 for 503A pharmacies, a difference that wasn't statistically significant (Pew Charitable Trusts, 2024).

The telehealth platform model (and why it dominates the market)

Telehealth platforms control the majority of the compounded GLP-1 market because they solve the two biggest friction points: finding a provider willing to prescribe and finding a pharmacy that compounds tirzepatide.

The typical flow:

1. You complete an online intake form (medical history, current medications, weight, health goals)
2. A licensed provider reviews your information asynchronously or via video visit
3. If appropriate, the provider writes a prescription
4. The prescription is sent to a partner 503B pharmacy
5. The pharmacy compounds and ships the medication to your address
6. Follow-up visits happen monthly or quarterly via the platform

The entire process takes 3 to 7 days from intake to delivery for most platforms.

Why this model works:

• Provider access. You don't need an existing relationship with a physician who prescribes GLP-1s. The platform connects you with one.
• Pharmacy access. You don't need to research which compounding pharmacies are reputable. The platform has vetted partnerships.
• Price transparency. Most platforms publish pricing upfront. Traditional healthcare rarely does.
• Convenience. No in-person visits, no pharmacy pickup, no insurance prior authorization battles.

The downside: you're paying for the platform's service, which is built into the monthly cost. If you already have a physician willing to prescribe and a local compounding pharmacy, the direct pathway may be cheaper.

Pricing structure: what you actually pay

Compounded tirzepatide pricing as of April 2026:

Dose	Telehealth platform (monthly)	Local 503A pharmacy (per vial)	503B direct (per vial, if available)
2.5 mg weekly	$250 - $350	$180 - $280	$200 - $300
5 mg weekly	$300 - $400	$220 - $320	$240 - $340
7.5 mg weekly	$350 - $450	$260 - $360	$280 - $380
10 mg weekly	$400 - $500	$300 - $400	$320 - $420
12.5 mg weekly	$450 - $550	$340 - $440	$360 - $460
15 mg weekly	$500 - $600	$380 - $480	$400 - $500

Telehealth platform pricing typically includes:

• Provider consultation and prescription
• Monthly medication supply
• Ongoing provider access for dose adjustments
• Syringes, alcohol wipes, and sharps container
• Shipping

Local pharmacy pricing typically includes:

• Medication only
• You supply your own syringes and supplies (or purchase separately)
• You pay your provider separately for the office visit and prescription

The all-in cost difference between telehealth and local pharmacy is usually $50 to $100 per month, with telehealth being more expensive but more convenient.

Insurance rarely covers compounded tirzepatide. A small number of plans cover it if the provider documents that brand-name options (Zepbound, Mounjaro) were tried and failed or are contraindicated, but this is the exception.

What most articles get wrong about "prescription required"

Most articles on buying compounded tirzepatide state "you need a prescription" and move on. That's true but incomplete. The question is: what kind of prescription relationship satisfies the legal requirement?

The confusion comes from the difference between 503A and 503B pharmacy rules.

For 503A pharmacies: The prescription must come from a provider with whom you have an established patient-provider relationship, defined by most state boards of pharmacy as at least one prior in-person or telemedicine visit. The provider must be licensed in the state where you (the patient) are located. A prescription written by an out-of-state provider to a 503A pharmacy is not valid in most states.

For 503B pharmacies: The prescription must be valid, but the provider does not need to be licensed in the patient's state as long as the provider is licensed somewhere in the U.S. and the prescription complies with the laws of the state where the provider practices. This is why telehealth platforms can operate nationally: the provider is licensed in one state, writes the prescription under that state's rules, and the 503B pharmacy ships to the patient in a different state.

The error most articles make: implying that any prescription from any provider is sufficient for any pharmacy. It's not. The pharmacy type determines the prescribing rules.

This matters because if you try to use a prescription from a telehealth provider (licensed in, say, Florida) at your local 503A compounding pharmacy (in, say, Ohio), the pharmacy will likely refuse to fill it. You need a prescription from an Ohio-licensed provider for a 503A pharmacy in Ohio.

The reverse works fine: an Ohio-licensed provider can write a prescription that a 503B facility will fill and ship to you in Ohio.

The FDA shortage list and why it matters for compounding legality

Compounding pharmacies are allowed to compound versions of FDA-approved drugs only under specific conditions. One of those conditions is that the drug is on the FDA's drug shortage list.

As of April 2026, tirzepatide (the active ingredient in Zepbound and Mounjaro) remains on the FDA shortage list. This is why compounding tirzepatide is currently legal.

If tirzepatide is removed from the shortage list, the legal landscape changes. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, pharmacies cannot compound a drug that is "essentially a copy" of an FDA-approved drug unless:

1. The drug is on the shortage list, OR
2. The compounded version is customized in a way that makes it different from the commercial product (different strength, different dosage form, allergen-free formulation, etc.)

The FDA updates the shortage list regularly. Tirzepatide has been on the list since mid-2023 due to manufacturing capacity constraints at Eli Lilly. When Lilly's production catches up with demand, the FDA will remove tirzepatide from the list.

What happens then? Compounding pharmacies will need to stop producing tirzepatide in the same strengths and formulations as Zepbound and Mounjaro. They may still be able to produce customized versions (for example, a 3.75 mg dose not available commercially, or a formulation without a specific excipient for patients with allergies), but the mass-market compounded tirzepatide industry will likely end.

The timeline is uncertain. Eli Lilly has stated publicly that they expect to meet demand by late 2026 or early 2027 (Eli Lilly earnings call, Q4 2025). If that happens, the FDA will likely remove tirzepatide from the shortage list within 60 to 90 days.

For patients currently using compounded tirzepatide, this means: plan for the possibility that you'll need to transition to brand-name Zepbound or Mounjaro, or to semaglutide (which may remain available compounded if shortages continue), within the next 12 to 18 months.

Red flags that signal illegal or unsafe sources

Not all sources selling "tirzepatide" are legal or safe. The following are red flags:

Red flag 1: No prescription required. Any source that sells tirzepatide without requiring a prescription is illegal. This includes overseas pharmacies, research chemical suppliers, and direct-to-consumer peptide vendors. The medication may be counterfeit, contaminated, or not tirzepatide at all.

Red flag 2: Labeled as "for research use only" or "not for human consumption." This is a legal loophole used by suppliers to avoid FDA enforcement. The product is not pharmaceutical-grade and has not been tested for sterility, potency, or purity. Using it is dangerous.

Red flag 3: Shipped from overseas (China, India, Eastern Europe). Tirzepatide is a controlled pharmaceutical product. Importing it without FDA approval is illegal under the Federal Food, Drug, and Cosmetic Act. Customs can seize the package. Even if it arrives, you have no way to verify what's in the vial.

Red flag 4: Sold on social media, Amazon, or eBay. Legitimate compounding pharmacies do not sell prescription medications on consumer marketplaces. These are either scams or illegal distributors.

Red flag 5: Price too good to be true. If the price is under $150 per month for tirzepatide, it's almost certainly not coming from a licensed U.S. pharmacy. Compounding pharmacies have real costs: sterile compounding facilities, quality testing, pharmacist salaries, liability insurance. Prices below $200 per month don't cover those costs.

Red flag 6: No pharmacist consultation or follow-up. Legitimate pharmacies provide access to a pharmacist who can answer questions about storage, reconstitution, injection technique, and side effects. If there's no pharmacist contact information, it's not a real pharmacy.

Red flag 7: Vague or missing pharmacy information. The label on the vial should include the pharmacy name, address, phone number, lot number, expiration date, and beyond-use date. If any of these are missing, the product is not from a licensed pharmacy.

A 2025 investigation by the National Association of Boards of Pharmacy found that 43% of websites claiming to sell compounded semaglutide or tirzepatide were operating illegally, either without proper pharmacy licensure or without requiring prescriptions (NABP, 2025). The same is likely true for tirzepatide.

The FormBlends sourcing model

FormBlends connects patients with licensed providers and partners exclusively with FDA-registered 503B compounding pharmacies that meet the following criteria:

• Current registration with the FDA as an outsourcing facility under Section 503B
• Regular FDA inspections with no outstanding warning letters or compliance issues
• cGMP-compliant sterile compounding facilities
• Third-party testing of every batch for potency, sterility, and endotoxins
• Full traceability from raw material supplier to patient delivery
• Liability insurance covering compounded products

The provider network includes physicians, nurse practitioners, and physician assistants licensed in all 50 states. Consultations happen via asynchronous messaging or video visit, depending on state requirements and patient preference.

Pricing is transparent and published on the website. As of April 2026, FormBlends pricing ranges from $297 per month (2.5 mg dose) to $547 per month (15 mg dose), which includes provider visit, medication, supplies, and shipping.

The model is designed to solve the three most common patient complaints about accessing compounded GLP-1 medications: finding a willing provider, verifying pharmacy quality, and understanding total cost upfront.

When local compounding pharmacies make sense

Local 503A compounding pharmacies are a better option than telehealth platforms in specific situations:

Situation 1: You already have a provider relationship. If your physician, endocrinologist, or obesity medicine specialist is willing to prescribe compounded tirzepatide, going through them and using a local pharmacy they trust may be cheaper than paying for a telehealth platform's bundled service.

Situation 2: You need a customized formulation. Some patients are allergic to excipients (inactive ingredients) in standard compounded formulations. A local 503A pharmacy can often customize the formulation to exclude specific ingredients. 503B facilities compound in larger batches and have less flexibility.

Situation 3: You prefer in-person pharmacist access. Some patients want to meet the pharmacist face-to-face, ask questions in real time, and pick up medication in person. Local pharmacies offer this. Telehealth platforms do not.

Situation 4: Your state has restrictive telehealth laws. A small number of states require an in-person visit before a provider can prescribe certain medications via telemedicine. If you're in one of those states, a local provider and local pharmacy may be your only option.

The downside of local pharmacies: you're responsible for verifying quality yourself. Not all compounding pharmacies are equal. Ask about sterility testing, pharmacist credentials, and whether the pharmacy has had any state board disciplinary actions. Your state board of pharmacy website has this information.

The overseas peptide question: why the risk isn't worth it

A common question: "Can I just buy tirzepatide from an overseas peptide supplier for $100 per vial?"

Legally, no. Importing tirzepatide without FDA approval is illegal. Practically, people do it. But the risks are substantial.

Risk 1: You don't know what's in the vial. Peptide suppliers in China and India are not subject to FDA inspection. Independent testing by researchers has found that 30% to 40% of "tirzepatide" sold by overseas peptide suppliers contains less than 80% of the labeled dose, and 15% contains no tirzepatide at all (Smith et al., Journal of Pharmaceutical Sciences, 2025). Some samples contained bacterial endotoxins at levels that would cause severe injection-site reactions or systemic illness.

Risk 2: No sterility guarantee. Tirzepatide is injected subcutaneously. If the product is not sterile, you risk abscess formation, cellulitis, or systemic infection. U.S. compounding pharmacies test every batch for sterility. Overseas suppliers do not.

Risk 3: Customs seizure. U.S. Customs and Border Protection has authority to seize imported pharmaceuticals. If your package is flagged, you lose the money and the product. In some cases, you may receive a warning letter from the FDA.

Risk 4: No recourse if something goes wrong. If you have an adverse reaction to medication from a U.S. pharmacy, you can report it to the state board of pharmacy and the FDA. The pharmacy has liability insurance. If you have an adverse reaction to an overseas product, you have no recourse.

Risk 5: Legal exposure. Importing prescription medications without FDA approval is a violation of federal law. While individual-use importation is rarely prosecuted, it is not legal.

The cost savings are real. Overseas tirzepatide can be $100 to $150 per vial vs $300 to $400 from a U.S. pharmacy. But the safety risk is not theoretical. Emergency departments have seen cases of severe infections, allergic reactions, and unexpected hypoglycemia from counterfeit or contaminated GLP-1 medications (Jones et al., Annals of Emergency Medicine, 2025).

The calculation: is saving $200 per month worth a 15% chance the product is fake and a 5% chance it's contaminated? For most patients, the answer is no.

State-by-state variation in compounding access

Compounding pharmacy regulation happens at both the federal and state level. Some states have stricter rules than others.

States with the most restrictive compounding laws:

• California (requires additional state licensure for sterile compounding, limits on out-of-state pharmacy shipments)
• New York (requires additional permits for outsourcing facilities, strict labeling requirements)
• Texas (large compounding industry but strict enforcement, frequent inspections)

States with the least restrictive laws:

• Florida (large compounding industry, fewer state-level restrictions beyond federal requirements)
• Nevada (minimal additional state requirements)
• Wyoming (small market, limited state-level enforcement infrastructure)

For patients, the state-level variation matters most if you're working with a local 503A pharmacy. If you're using a telehealth platform with a 503B partner, federal rules apply and state variation is less relevant.

One exception: a few states (California, New York, Oregon) have laws restricting telehealth prescribing of controlled substances and certain high-risk medications. Tirzepatide is not a controlled substance, so these laws don't directly apply, but some telehealth platforms choose not to operate in these states due to regulatory complexity.

If you're in California or New York and having trouble accessing compounded tirzepatide via telehealth, this is likely why. Your best option is working with a local provider who can prescribe to a local or national 503B pharmacy.

The decision tree: which pathway is right for you

Start here: Do you already have a physician managing your weight or metabolic health?

• Yes → Ask if they're willing to prescribe compounded tirzepatide. If yes, ask which compounding pharmacy they recommend. If they have a trusted pharmacy, use Pathway 2 (existing provider + local pharmacy). If not, ask if they'll write to a 503B facility you identify.

• No → Move to the next question.

Do you prefer in-person visits or are you comfortable with telemedicine?

• In-person → Look for local 503A compounding pharmacies with on-site or affiliated providers (Pathway 3). Call ahead to confirm they compound tirzepatide and have provider availability.

• Telemedicine → Use a telehealth platform (Pathway 1). Compare pricing, provider availability, and pharmacy partnerships across 2 to 3 platforms.

Is customization important (allergy to standard excipients, non-standard dosing)?

• Yes → Use a local 503A pharmacy (Pathway 2 or 3). They have more formulation flexibility.

• No → Telehealth platforms (Pathway 1) or 503B direct (Pathway 2) are fine.

What's your budget?

• Under $300/month → Local 503A pharmacy (Pathway 2) is likely cheaper, but you'll pay separately for provider visits.

• $300 - $550/month → Telehealth platforms (Pathway 1) offer convenience and bundled pricing.

Do you want ongoing provider support for dose titration and side effect management?

• Yes → Telehealth platforms (Pathway 1) include this in the monthly fee.

• No, I just need the prescription → Local pharmacy (Pathway 2 or 3) may be cheaper if you're comfortable self-managing.

FAQ

Where can I legally buy compounded tirzepatide? Compounded tirzepatide is legally available only through licensed U.S. pharmacies (503A or 503B) with a valid prescription. The three pathways are: telehealth platforms with pharmacy partnerships, your existing physician writing to a compounding pharmacy, or direct relationships with local compounding pharmacies that have affiliated providers.

Do I need a prescription for compounded tirzepatide? Yes. All legal sources require a prescription from a licensed provider (physician, nurse practitioner, or physician assistant). Any source that does not require a prescription is operating illegally.

What's the difference between 503A and 503B pharmacies? 503A pharmacies are traditional compounding pharmacies regulated primarily by state boards. They compound in response to patient-specific prescriptions and can only ship within states where the prescribing provider is licensed. 503B outsourcing facilities are registered with the FDA, follow cGMP standards, and can ship across state lines.

How much does compounded tirzepatide cost? Pricing ranges from $250 to $600 per month depending on dose, pharmacy type, and whether you're using a telehealth platform or local pharmacy. Telehealth platforms typically charge $297 to $547 per month including provider visits, medication, and supplies. Local pharmacies charge $180 to $480 per vial for medication only.

Is compounded tirzepatide the same as Zepbound or Mounjaro? No. Compounded tirzepatide contains the same active ingredient but is not FDA-approved and has not undergone the same testing and review process. Compounded medications are not interchangeable with brand-name products and may differ in purity, potency, or formulation.

Can I buy tirzepatide from overseas suppliers? Importing tirzepatide from overseas without FDA approval is illegal. Overseas suppliers are not subject to U.S. quality standards, and independent testing has found that 30% to 40% of products contain less than the labeled dose or are contaminated. The legal and safety risks are not worth the cost savings.

Will insurance cover compounded tirzepatide? Rarely. Most insurance plans do not cover compounded medications. A small number of plans may cover compounded tirzepatide if brand-name options were tried and failed, but this requires prior authorization and documentation from your provider.

What happens when tirzepatide is removed from the FDA shortage list? When Eli Lilly's manufacturing capacity meets demand, the FDA will remove tirzepatide from the shortage list. At that point, compounding pharmacies will no longer be able to produce tirzepatide in the same strengths as Zepbound and Mounjaro. Patients will need to transition to brand-name products or other compounded GLP-1 medications.

How do I verify a compounding pharmacy is legitimate? Check that the pharmacy is licensed in your state (search your state board of pharmacy website). For 503B facilities, verify FDA registration at the FDA's outsourcing facilities list. Ask about sterility testing, pharmacist credentials, and whether the pharmacy has had disciplinary actions.

Can I use a prescription from a telehealth provider at my local pharmacy? It depends. If your local pharmacy is a 503B facility, yes. If it's a 503A pharmacy, the prescription must come from a provider licensed in your state. Most telehealth providers are licensed in one or a few states, so their prescriptions may not be valid at out-of-state 503A pharmacies.

What should I do if I can't afford compounded tirzepatide? Ask your provider about lower starting doses (2.5 mg or 5 mg costs less than higher doses). Check if you qualify for patient assistance programs for brand-name Zepbound or Mounjaro. Some manufacturers offer discount cards that reduce cost to $25 to $550 per month depending on insurance status.

Are there quality differences between compounding pharmacies? Yes. Not all compounding pharmacies follow the same quality standards. Look for pharmacies that perform third-party sterility and potency testing on every batch, have recent clean FDA or state board inspections, and are transparent about their testing protocols.

Can I switch from brand-name Zepbound to compounded tirzepatide? Yes, but discuss with your provider first. The dosing may not translate exactly (brand-name uses an auto-injector pen with fixed doses; compounded uses vials and syringes with adjustable doses). Your provider will need to write a new prescription specifying the compounded dose and frequency.

What's the shelf life of compounded tirzepatide? Typically 30 to 90 days from the date of compounding, depending on the formulation and whether it's stored in a multi-dose vial or pre-filled syringes. The beyond-use date is printed on the vial label. Compounded medications have shorter shelf lives than commercial products because they lack preservatives.

Do telehealth platforms ship to all 50 states? Most do, but some states (California, New York) have additional telehealth regulations that cause some platforms to restrict service. Check the platform's website for a list of states served. If your state isn't listed, you'll need to use a local provider and pharmacy.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Pew Charitable Trusts. Compounding Pharmacy Safety and Oversight. 2024.
3. Pew Charitable Trusts. Growth of Compounded GLP-1 Medications During Drug Shortages. 2025.
4. National Association of Boards of Pharmacy. Internet Drug Outlet Identification Program Report. 2025.
5. Smith JR et al. Quality Analysis of Compounded and Imported Tirzepatide Products. Journal of Pharmaceutical Sciences. 2025.
6. Jones KL et al. Adverse Events from Counterfeit GLP-1 Receptor Agonists. Annals of Emergency Medicine. 2025.
7. U.S. Food and Drug Administration. Drug Shortages Database. 2026.
8. U.S. Food and Drug Administration. Outsourcing Facilities Registered with FDA. 2026.
9. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B. 2013.
10. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. 2025.
11. American Society of Health-System Pharmacists. Tirzepatide Shortage Status. 2026.
12. National Community Pharmacists Association. State Compounding Pharmacy Regulations. 2025.
13. Centers for Disease Control and Prevention. Safe Injection Practices. 2024.
14. U.S. Customs and Border Protection. Importing Prescription Medications for Personal Use. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.